Description

REGENOVUE Sub-Q Plus with Lidocaine

REGENOVUE Sub-Q Plus is a professional cross-linked hyaluronic acid dermal filler with lidocaine. Supplied as one sterile 1.1ml prefilled syringe, it has the firmest gel profile in the REGENOVUE Plus range and is intended for qualified professional assessment of suitable deep-support and facial-contouring applications.

The formulation contains 24mg/ml of cross-linked hyaluronic acid and 0.3% lidocaine. The incorporated lidocaine is intended to improve patient comfort during administration. REGENOVUE Sub-Q Plus is manufactured in South Korea by NeoGenesis Co., Ltd.

REGENOVUE Sub-Q Plus must only be purchased and administered by appropriately qualified, trained and insured healthcare or aesthetic professionals.

What Is REGENOVUE Sub-Q Plus Used For?

REGENOVUE Sub-Q Plus is the largest-particle, lidocaine-containing filler in the REGENOVUE Plus range. Manufacturer product information positions it for professional lower-subcutaneous placement, where a high-support gel may be appropriate.

Depending on the patient’s anatomy, tissue characteristics, vascular anatomy and individual treatment plan, a qualified practitioner may consider REGENOVUE Sub-Q Plus for selected facial contouring, deep facial folds, chin, cheek or jawline treatments. These are general product-positioning examples and are not treatment recommendations for every patient.

The treating professional must determine whether this product, the intended treatment area, placement depth, quantity and technique are appropriate after a full consultation and individual risk assessment.

REGENOVUE Sub-Q Plus Product Specifications

• Product: REGENOVUE Sub-Q Plus with Lidocaine
• Product type: Cross-linked hyaluronic acid dermal filler
• Hyaluronic acid concentration: 24mg/ml
• Lidocaine concentration: 0.3% or 3mg/ml
• Formulation: Monophasic cross-linked hyaluronic acid gel
• Presentation: One 1.1ml prefilled syringe
• Recommended professional positioning: Lower subcutaneous tissue
• Needles: One 27G and one 25G sterile needle, subject to supplied packaging
• Manufacturer: NeoGenesis Co., Ltd.
• Country of manufacture: South Korea
• Storage: 2°C to 25°C, protected from direct sunlight
• Use: Professional aesthetic use only

Always check the physical carton to confirm the exact syringe volume, supplied accessories, batch number, expiry date and current manufacturer instructions before treatment or publication.

Key Features of REGENOVUE Sub-Q Plus

• Professional cross-linked hyaluronic acid dermal filler
• Contains 24mg/ml hyaluronic acid
• Contains 0.3% lidocaine
• Firm, high-support gel profile
• Designed for suitable deep professional applications
• Supplied as a sterile 1.1ml prefilled syringe
• Part of the REGENOVUE Plus lidocaine-containing range
• Manufactured by NeoGenesis in South Korea

Cross-Linked Hyaluronic Acid

Hyaluronic acid is naturally present within the human body and contributes to tissue hydration and structure. In a dermal filler, cross-linking creates a gel that can provide temporary physical support when correctly placed in suitable tissue by a qualified professional.

REGENOVUE Sub-Q Plus has a firmer and more supportive gel profile than REGENOVUE Fine Plus or REGENOVUE Deep Plus. It should be selected only where the practitioner considers a high-support filler appropriate for the anatomy, intended tissue depth and treatment objective.

Hyaluronic acid fillers are not permanent implants. Treatment response and visible duration can vary according to placement, quantity, treatment area, individual metabolism, lifestyle and tissue characteristics. No particular result or duration can be guaranteed.

REGENOVUE Sub-Q Plus Compared with Other REGENOVUE Fillers

• REGENOVUE Fine Plus: Fine gel profile for suitable upper-dermis applications.
• REGENOVUE Deep Plus: Medium gel profile for suitable lower-dermis and upper-subcutaneous applications.
• REGENOVUE Sub-Q Plus: Firm gel profile for suitable lower-subcutaneous support applications.

The “Plus” designation identifies REGENOVUE products containing lidocaine. The appropriate product should be selected according to individual anatomy, intended treatment area, tissue depth and required support—not simply according to the severity of a visible line.

Professional Consultation and Patient Assessment

Before using REGENOVUE Sub-Q Plus, the practitioner should review the patient’s medical history, allergies, medication, previous aesthetic procedures, skin condition and treatment expectations. The intended treatment area should be assessed for infection, inflammation, irritation, broken skin or another factor that could make treatment unsuitable.

Patients should receive clear information about the planned treatment, realistic limitations, possible adverse effects, aftercare and alternative options. Informed consent should be obtained before treatment. Product traceability details, including batch number and expiry date, should be documented in the patient record.

Important Safety Information

REGENOVUE Sub-Q Plus must never be injected into a blood vessel. Accidental intravascular administration of any dermal filler can cause serious complications, including vascular occlusion, tissue damage, skin necrosis, visual impairment, blindness or stroke.

Administration requires detailed facial-anatomy knowledge, aseptic technique and the ability to recognise and manage complications promptly. Qualified practitioners should maintain appropriate emergency procedures, equipment and referral arrangements.

Do not use REGENOVUE Sub-Q Plus in patients with known hypersensitivity to hyaluronic acid, lidocaine, amide-type local anaesthetics or another product component. Do not treat areas affected by active infection, inflammation, irritation, broken skin, untreated skin disease or an active cold-sore outbreak.

Pregnancy, breastfeeding, immune conditions, anticoagulant medication, bleeding disorders, significant allergies, recent treatment in the same area and a history of problematic scarring require careful professional consideration. Review the supplied manufacturer instructions before use.

Possible Treatment Reactions

Temporary injection-site reactions may include redness, swelling, tenderness, bruising, itching, firmness, discomfort or discolouration. Less common complications can be serious and may require urgent professional assessment.

Patients should receive written aftercare information and clear contact instructions. Unexpected or increasing pain, skin blanching, unusual colour changes, visual symptoms or neurological symptoms require immediate professional attention.

Storage, Handling and Traceability

Store REGENOVUE Sub-Q Plus at 2°C to 25°C and protect it from direct sunlight unless the supplied carton states otherwise. Do not use the product if its sterile packaging is damaged, the expiry date has passed, the gel appears abnormal or storage conditions cannot be verified.

The prefilled syringe and supplied needles are single-use devices. Do not reuse or resterilise them. Dispose of used equipment and unused product through appropriate clinical and sharps-waste procedures.

Order REGENOVUE Sub-Q Plus

REGENOVUE Sub-Q Plus with Lidocaine is available from The Clinic Vault for eligible professional purchasers. Customers are responsible for ensuring that they have the qualifications, training, insurance and legal authority required to purchase and administer injectable aesthetic products.

Explore our professional aesthetic product collection or review available REGENOVUE product information before procurement.

Professional-use notice: This page provides product-identification and professional-procurement information only. It does not replace supplied manufacturer instructions, accredited clinical training, local regulations, professional judgement or an individual patient assessment.